

<b>INFORMATION DISCLOSURE STATEMENT</b> P E J C 174 05 2003 RADEMA	Applicant(s): Antonio J. Grillo-Lopez et al.	Examiner: Quang Nguyen
	Filing Date: July 10, 2000	Group Art Unit: 1636

### U.S. PATENT DOCUMENTS


Examiner (initials)	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
mh	119	60/105,014	10/20/1998	Raubitschek et al.			
mh	120	2003/0026801 A1	02/06/2003	Weiner et al.			
mh	121	2003/0021781 A1	01/30/2003	Anderson et al.			
mh	122	2002/0197256 A1	12/26/2002	Grewal			
mh	123	2002/0197255 A1	12/26/200	Anderson et al.			
mh	124	2002/0128488 A1	09/12/2002	Yamakawa et al.			
mh	125	2002/0004587 A1	01/10/2002	Miller et al.			
mh	126	6,528,624 B1	03/04/2003	Idusogie et al.			
mh	127	6,410,391 B1	06/25/2002	Zelsacher			
mh	128	6,368,596 B1	04/09/2002	Ghetie et al.			
mh	129	6,287,537 B1	09/11/2001	Kaminski et al.			
mh	130	6,242,195 B1	06/05/2001	Idusogie et al.			
mh	131	6,224,866 B1	05/01/2001	Barbera-Guillem			
mh	132	6,194,551 B1	02/27/2001	Idusogie et al.			
mh	133	6,171,586 B1	01/09/2001	Lam et al.			
mh	134	6,090,365	07/18/2000	Kaminsky et al.			
mh	135	6,015,542	01/18/2000	Kaminsky et al.			
mh	136	5,849,898	12/15/1998	Seed et al.			
mh	137	5,843,439	12/01/1998	Anderson et al.			
mh	138	5,843,398	12/01/1998	Kaminsky et al.			
mh	139	4,861,579	08/29/1989	Meyer, Jr. et al.			
mh	140	2003/0133930 A1	7/17/2003	Goldenberg et al.			

### FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
mh	141	WO 02/102312 A2	12/27/2002	PCT				
mh	142	WO 02/096948 A2	12/05/2002	PCT				
mh	143	WO 02/079255 A1	10/10/2002	PCT				
mh	144	WO 02/04021 A1	01/17/2002	PCT				
mh	145	WO 01/80884 A1	11/01/2001	PCT				
mh	146	WO 01/77342 A1	10/18/2001	PCT				
mh	147	WO 01/74388 A1	10/11/2001	PCT				
mh	148	WO 01/10461 A1	02/15/2001	PCT				
mh	149	WO 00/72333 A1	11/30/2000	PCT				
mh	150	WO 00/67795 A1	11/16/2000	PCT				
mh	151	WO 00/44788 A1	08/03/2000	PCT				
mh	152	WO 99/22764 A1	05/14/1999	PCT				
mh	153	WO 98/58964 A1	12/30/1998	PCT				

EXAMINER <i>Maheer Haddad</i>	DATE CONSIDERED <i>1/6/04</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449)	SHEET 1 OF 2

INFORMATION DISCLOSURE STATEMENT	Docket No. 22338-602	Application No. 09/613,034
	Applicant(s): Antonio J. Grillo-Lopez et al.	Examiner: Quang Nguyen
	Filing Date: July 10, 2000	Group Art Unit: 1636



### FOREIGN PATENT DOCUMENTS (CONTINUED)

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
154	WO 98/56418 A1	12/17/1998	PCT				
155	EP 0 330 191 B1	10/02/1996	Europe				
156	WO 0042072 A3	07/20/2000	PCT				
157	WO 00/20864 A1	04/13/2000	PCT				
158	WO 99/51642 A1	10/14/1999	PCT				

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

159	Eisenberg, R. "Anti B-Cell Therapy in the Treatment of Autoimmune Disease." Genentech Oncology and IDEC Pharmaceuticals Investigator-Sponsored Protocol Concept Worksheet.
160	Gryn, J. Clinical Research Proposal.
161	Latov, N. "Rituxan for Treatment of Neuropathy and IgM Monoclonal Gammopathy with Anti-MAG or Sulfatide Antibody Activity." New Clinical Study Application.
162	Looney, R.J. Clinical Research Proposal. 1/15/1999
163	Pestronk, A. "A study of Rituxan in the treatment of polyneuropathies associated with serum IgM autoantibodies." Clinical Research Proposal.
164	Saleh et al. "A Phase II Study of Rituxan in the Treatment of Immune Thrombocytopenic Purpura." Clinical Research Proposal. 10/1/1998
165	Friend et al. "Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection." Transplantation, Vol. 68, 1999, pp. 1625-1631.
166	Edwards, J.C.W. et al. "Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes." Rheumatology, Vol. 40, 2001, pp. 205-211.
167	Edwards, J.C.W. et al. "B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders." Biochemical Society Transactions, Vol. 30, part 4, 2002, pp. 824-828.
168	Eisenberg, Robert A. Genentech Investigator-Sponsored Protocol Concept Worksheet
169	Leandro, M.J. et al. "Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion." Ann Rheum Dis, Vol. 61, 2002, pp. 883-888.
170	Leandro, M.J. et al. "An Open Study of B Lymphocyte Depletion in Systemic Lupus Erythematosus." Arthritis & Rheumatism, Vol. 46, No. 10, October 2002, pp. 2673-2677.
171	Matthews, Robert. "Medical Heretics." New Scientist, April 7, 2001, pp. 34-37.
172	Stasi, R. et al. "Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura." Blood, Vol. 98, No. 4, August 2001, pp. 952-957.
173	Juan M. Arnada et al.; Anti-CD20 Monoclonal Antibody (Rituximab) Therapy for Acute Cardiac Humoral Rejection: A Case Report; Transplantation, 2000, pp. 907-910
174	Voravit Ratanatharathorn et al. "Anti-CD20 Monoclonal Antibody Treatment of Refractory Immune-Mediated Thrombocytopenia in a Patient with Chronic Graft-versus-Host Disease", Annals of Internal Medicine, August 2000, pp. 275-279
175	C. Anasetti et al. "Graft-v-Host Disease is Associated with Autoimmune-like Thrombocytopenia", The Journal of The American Society of Hematology, Vol. 73, No. 4, March 1989, pp. 1054-1058

EXAMINER <i>Maha Haddad</i>	DATE CONSIDERED <i>1/6/03</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449)	SHEET 2 OF 2

PTO-1449

NOV 05 2003

U.S. Dept. of Commerce  
Patent and Trademark OfficeAny Docket No.  
P1752R1Serial No.  
09/613,038

## LIST OF DISCLOSURES COVERED BY APPLICANT

(Use several sheets if necessary)

Applicant  
Grillo-Lopez et al.Filing Date  
10 Jul 2000Group  
1636

## U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
QN	1	4,975,278	04.12.90	Senter, P. et al.	424	178.1	
	2	5,417,972	23.05.95	Bhat, N. M. et al.	424	137.1	
	3	5,540,926	30.07.96	Aruffo, A. et al.	424	153.1	
	4	5,587,459	24.12.96	Uckun	530	391.1	
	5	5,593,676	14.01.97	Bhat, N. M. et al.	424	137.1	
	6	5,595,721	21.01.97	Kaminski et al.	424	1.49	
	7	5,677,180	14.10.97	Robinson et al.	435	328	
	8	5,686,072	11.11.97	Uhr et al.	424	18.1	
	9	5,693,780	02.12.97	Newman, R. A. et al.	536	23.53	
	10	5,721,108	24.02.98	Robinson et al.	435	7.23	
	11	5,736,137	07.04.98	Anderson et al.	424	133.1	
	12	5,786,456	28.07.98	Ledbetter, J. A. et al.	530	388.73	
	13	5,795,569	18.08.98	Bartley et al.	424	85.1	
	14	5,872,223	16.02.99	Uckun	530	801.1	
	15	5,877,299	02.03.99	Thomas et al.	530	413	

## FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
M+	16	405,972 A1 ✓	02.01.91	EPO				
	17	540,859 B1 ✓	14.01.98	EPO				
	18	585,943 B1 ✓	11.02.98	EPO				
	19	701,130 A2 ✓	13.03.96	EPO				
	20	WO 00/06694 ✓	10.02.00	PCT				
	21	WO 00/09160 ✓	24.02.00	PCT				
	22	WO 00/27428 ✓	18.05.00	PCT				
	23	WO 00/27433 ✓	18.05.00	PCT				
	24	WO 91/13974 ✓	19.09.91	PCT				
	25	WO 93/25673 ✓	23.12.93	PCT				
	26	WO 95/03770 ✓	09.02.95	PCT				
	27	WO 95/14230 ✓	26.05.95	PCT				
	28	WO 97/13529 ✓	17.04.97	PCT				
	29	WO 97/31025 ✓	28.08.97	PCT				
	30	WO 97/34633 ✓	25.09.97	PCT				
	31	WO 98/04281 ✓	05.02.98	PCT				
	32	WO 98/16254 ✓	23.04.98	PCT				
	33	WO 99/30738 ✓	24.06.99	PCT				


Examiner

Mahn Haddad

Date Considered

1/6/04

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		U.S. Dept. of Commerce Patent and Trademark Office		Docket No. P1752R1	Serial No. 09/613,038
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)				Applicant Grillo-Lopez et al.	
Filing Date 10 Jul 2000				Group 1636	
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>					
MH	34	"Amgen Discontinues Development of MAb" (press release) (September 11, 1998)			
MH	35	Anderson et al., "Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation" <u>Blood</u> 63(6):1424-1433 (1984)			
QN	36	Ballester et al., "Rituximab can be safely included as part of high-dose therapy/autologous stem cell transplantation for patients with Non-Hodgkin's lymphoma" <u>Blood</u> (Abstract #4552) 92(10 Suppl. 1 part 1-2):360b-361b (Nov 15, 1998)			
MH	37	Bellon et al., "Aerosol Administration of a Recombinant Adenovirus Expressing CFTR to Cystic Fibrosis Patients: A Phase I Clinical Trial" <u>Human Gene Therapy</u> 8:15-25 (1997)			
QN	38	Buckstein et al., "The effects of in vivo purging with Rituxan on stem cell mobilization efficacy, harvest purity, cytokine profile and engraftment in patients with relapsed follicular lymphoma undergoing autologous stem cell transplant" <u>Blood</u> (Abstract #2672) 92(10 Suppl. 1 Part 1-2):647a (1998)			
MH	39	Bussel, J.B., "Autoimmune Thrombocytopenic Purpura" <u>Hematology - Oncology Clinics of North America</u> 4(1):179-191 (Feb 1990)			
MH	40	Christ et al., "Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response" <u>Immunology Letters</u> 57:19-25 (1997)			
QN	41	Cook et al., "Effective Treatment of Lymphoproliferative Disease following Lung Transplantation using Monoclonal Anti-CD20 B-Cell Antibody" <u>The Journal of Heart and Lung Transplantation</u> (abstract only) 18:84-85 (January 1999)			
MH	42	Demidem et al., "Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs" <u>Cancer Biotherapy &amp; Radiopharmaceuticals</u> 12(3):177-186 (1997)			
MH	43	Einfeld et al., "Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains" <u>EMBO Journal</u> 7(3):711-717 (1988)			
QN	44	Faye et al., "Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders" <u>Lancet</u> 352:1285 (Oct 17, 1998)			
QN	45	Flinn et al., "In vivo purging and adjuvant immunotherapy with Rituximab during PBSC transplant for NHL" <u>Blood</u> (Abstract #2673) 92(10 Suppl 2 part 1-2):648a (Nov 15, 1998)			
MH	46	George et al., "Idiopathic Thrombocytopenic Purpura: A Practice Guideline Developed by Explicit Methods for The American Society of Hematology" <u>Blood</u> 88(1):3-40 (Jul 1, 1996)			
QN	47	John et al., "Anti-CD20 monoclonal antibody for the treatment of post-transplant lymphoproliferative disease in a pediatric heart transplant recipient." <u>Journal of Investigative Medicine</u> 4(2):125A (Feb 1999)			
MH	48	Johnston, "Rituximab-Associated Immune Thrombocytopenic Purpura" <u>Blood</u> 94(10):4386 (1999)			
MH	49	Kiesel et al., "Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytotoxicity" <u>Leukemia Research</u> 11(12):1119-1125 (1987)			
MH	50	Knoell, "Clinical Aspects of Gene Therapy" <u>The Annals of Pharmacotherapy</u> 32:977-979 (September 1998)			
MH	51	Korholz et al., "Humoral immunodeficiency in patients after bone marrow transplantation" <u>Bone Marrow Transplantation</u> 18:1123-1130 (1996)			
QN	52	Lee et al., "Rituxan in the treatment of cold agglutinin disease" <u>Blood</u> 92(9):3490-3491 (Nov 1, 1998)			
Examiner		Maher Haddad Mary Nguyen		Date Considered 1/6/04 02/01/02	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

NOV 05 2003

U.S. Dept. of Commerce  
Patent and Trademark Office

City Docket No.

P1752R1

Serial No.

09/613,038

**LIST OF DISCLOSURES CITED BY APPLICANT**

(Use several sheets if necessary)

Applicant

Grillo-Lopez et al.

Filing Date

10 Jul 2000

Group

1636

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

[illegible]

Examiner

Date Considered \_\_\_\_\_

1/6 104

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NOV 05 2003

U.S. Dept. of Commerce  
Patent and Trademark Office

My Docket No.

P1752R1

Serial No.

09/613,038

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Grillo-Lopez et al.

Filing Date

10 Jul 2000

Group

1636

## OTHER DISCLOSURES (including Author, Title, Date, Pertinent Pages, etc.)

QN	53	Levine et al., "IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab" <u>Neurology</u> 52:1701-1704 (May 12, 1999)
MH	54	Maloney et al., "The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (nhl) cell lines" <u>Blood</u> (Abstract #2535) 88(10):637a (1996)
QN	55	Mow et al., "Rituximab for the Treatment of Refractory Immune Thrombocytopenic Purpura - Case Report" <u>Blood</u> 94:3526 (1999)
MH	56	Nadler et al., "B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes" <u>J. Immunol.</u> 131(1):244-250 (Jul 1983)
MH	57	Nadler et al., "Diagnosis and treatment of human leukemias and lymphomas utilizing monoclonal antibodies" <u>Progress in Hematology</u> , Brown, E., Grune & Stratton, Inc. Vol. XII:187-225 (1981)
MH	58	Nadler, L. <u>Lymphocyte Typing XI</u> , Renling et al., Springer Verlag Vol. 2:3-37 and Appendix (1986)
MH	59	Notoya et al., "Chronic cold agglutinin disease accompanied with an increase of CD20 <sup>+</sup> /CD5 <sup>+</sup> cells; a case report" <u>The Japanese Journal of Clinical Hematology</u> (English language abstract of attached Japanese article) 35(9):881-885 (Sep 1994)
MH	60	Ooto et al., "Quantitative Flowcytometric Analysis of B Cell Surface Antigens in Patients with Autoimmune Diseases" <u>The Japanese Journal of Clinical Pathology</u> (English language abstract of attached Japanese article) 43(4):381-384 (Apr 1995)
MH	61	Pai-Scherf et al., "A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab" (Clinical Research Proposal), 1998
MH	62	Paulus et al., "Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo" <u>Arthritis Rheum.</u> 33(4):477-484 (Apr 1990)
MH	63	Perrotta and Abuel, "Response of chronic relapsing ITP of 10 years duration to Rituximab" <u>Blood</u> (Abstract #3360) 92 (Nov 1998)
MH	64	Pescovitz, "Pilot Study of Rituxin (anti-CD20) for the reduction of high titered anti-HLA antibodies in patients with renal failure awaiting renal transplant." (Clinical Trial Proposal), 1999
MH	65	Pescovitz, "Pilot study of Rituxin (anti-CD20) for the reduction of high titered anti-HLA antibodies in patients with renal failure awaiting renal transplant." (Letter to Dr. Grillo-Lopez and Protocol Concept Sheet), 1998
MH	66	Piasecik, P., "New therapeutic monoclonal antibodies target kidney transplant rejection and cancer" <u>Journal of the American Pharmaceutical Association</u> 38(3):379-380 (May/Jun 1998)
QN	67	Reff et al., "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20" <u>Blood</u> 83(2):435-445 (Jan 15, 1994)
MH	68	Shan et al., "Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies" <u>Blood</u> 91(5):1644-1652 (Mar 1, 1998)
MH	69	Sollinger (Letter to Dr. Bonni S. Dutcher) (December 23, 1998)
MH	70	Sollinger, "Phase 2 trial using Rituxin to desensitize patients awaiting renal transplant" (Investigator Initiated Protocol Concept Worksheet), 1999
MH	71	Tedder et al., "The B cell surface molecule B1 is functionally linked with B cell activation and differentiation" <u>The Journal of Immunology</u> 135(2):973-979 (1985)
MH	72	Tedder et al., "The CD20 surface molecule of B lymphocytes functions as a calcium channel" <u>J. Cell. Biochem.</u> (Abstract # M 023) 14D:195 (1990)

Examiner

Maher Haddad

Date Considered

1/6/04

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.